O Shaughnessy Asset Management LLC Has $1.38 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

O Shaughnessy Asset Management LLC increased its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 43.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,291 shares of the medical instruments supplier's stock after purchasing an additional 1,610 shares during the quarter. O Shaughnessy Asset Management LLC's holdings in Insulet were worth $1,381,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in Insulet during the fourth quarter worth $36,000. SRS Capital Advisors Inc. boosted its position in Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares in the last quarter. Friedenthal Financial purchased a new stake in Insulet during the fourth quarter worth $57,000. TD Private Client Wealth LLC boosted its position in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after purchasing an additional 56 shares in the last quarter. Finally, Assetmark Inc. boosted its position in Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares in the last quarter.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by company insiders.

Remove Ads

Insulet Stock Performance

NASDAQ:PODD traded down $12.24 during midday trading on Thursday, reaching $252.49. 180,971 shares of the company traded hands, compared to its average volume of 716,309. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The firm has a market capitalization of $17.73 billion, a price-to-earnings ratio of 43.65, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a fifty day moving average price of $267.71 and a 200 day moving average price of $260.19.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The firm had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. On average, analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on PODD. Citigroup upped their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Raymond James reiterated an "outperform" rating and set a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Stifel Nicolaus increased their target price on Insulet from $245.00 to $293.00 and gave the stock a "hold" rating in a research report on Friday, February 21st. StockNews.com downgraded Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, Piper Sandler upped their price target on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and an average price target of $292.06.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.